Non-clear cell renal cell carcinoma: Management of papillary RCC

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC

Bladder cancer updates from the first half of 2025

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression

WCLC 2025: Latest in EGFR positive NSCLC

Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours

Treatment management of favourable risk and very favourable risk patients

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers

Key insights from head and neck research at ASCO 2025

Transforming cancer care in India: The Access Cancer Care Initiative

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance